0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
 
 
   Acacia Pharma to Participate in Jefferies Virtual Healthcare Conference 
 
   Cambridge, UK and Indianapolis, US -- 25 May 2021, 12:00 CEST: Acacia 
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company") 
(EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused 
on developing and commercializing novel products to improve the care of 
patients undergoing serious medical treatments such as surgery, invasive 
procedures, or chemotherapy, announces that management will present a 
corporate overview at the Jefferies Virtual Healthcare Conference on 
Tuesday, 1 June 2021 at 08:00 ET (14:00 CEST). 
 
   A replay of the presentation will be available on the Jefferies 
conference website to registered conference attendees for 30 days post 
the event. Presentation slides will also be made available after the 
event through the investor section (Financial Reports and Presentations) 
of the Company's website, www.acaciapharma.com. 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   Citigate Dewe Rogerson 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@citigatedewerogerson.com 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
available in the US for the management of postoperative nausea & 
vomiting (PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centred in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   www.acaciapharma.com 
 
 
 
 

(END) Dow Jones Newswires

May 25, 2021 06:00 ET (10:00 GMT)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024